| Name | SX-682 |
| Description | SX-682 is an orally available allosteric inhibitor of CXCR1 and CXCR2 that blocks tumor myeloid suppressor cell recruitment and enhances T cell activation and anti-tumor immunity, with the potential to treat castration-resistant prostate cancer. |
| In vitro | SX-682 significantly inhibits PMN-MDSC trafficking without altering CXCR2 ligand expression; combination with SX-682 enhances tumor growth inhibition or established tumor rejection following programmed death axis (PD-axis) immune checkpoint blockade or adoptive cell transfer of engineered T cells; CXCR1/2 are expressed on tumor cells, but SX-682 appears to have little direct antitumor effect on these cancer cells. [1] |
| In vivo | METHODS: SX-682 (500 mg/kg, oral, one week) was used to treat tumor suppressor model mice injected subcutaneously with MOC2 cells, and PMN-MDSC accumulation was evaluated by flow cytometry.
RESULTS SX-682 significantly reduced PMN-MDSC trafficking into MOC2 tumors, but SX-682 treatment did not alter the proliferation of tumor PMN-MDSC in tumor-bearing mice. The main mechanism of SX-682 is to inhibit PMN-MDSC trafficking into MOC2 tumors. [2] |
| Storage | Store at low temperature,Keep away from moisture | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (10.7 mM), Sonication is recommended.
DMSO : 130 mg/mL (278.25 mM), Sonication is recommended.
|
| Keywords | tumor | SX-682 | SX682 | SX 682 | suppressor | recruitment | myeloid-derived | MDSCs | Inhibitor | inhibit | immunity | CXCR2 | CXCR1 | CXCR | CXC chemokine receptors | cells | antitumor | allosteric |
| Inhibitors Related | AZD8309 | rac-NBI-74330 | Delmetacin | Tannic acid | Artemotil | CXCR2-IN-1 | Soquelitinib | Plerixafor octahydrochloride | Tanimilast | 3-Indoleglyoxylic acid | Nicotinamide N-oxide | CXCL-CXCR1/2-IN-1 |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Immuno-Oncology Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
